PROTAC therapy as a new targeted therapy for lung cancer.
PROTACs
argeted protein degradation
lung cancer
proteolysis targeting chimeras
targeted therapy
Journal
Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
19
09
2022
revised:
01
11
2022
accepted:
17
11
2022
pmc-release:
01
03
2024
pubmed:
24
11
2022
medline:
7
3
2023
entrez:
23
11
2022
Statut:
ppublish
Résumé
Despite recent advances in molecular therapeutics, lung cancer is still a leading cause of cancer deaths. Currently, limited targeted therapy options and acquired drug resistance present significant barriers in the treatment of patients with lung cancer. New strategies in drug development, including those that take advantage of the intracellular ubiquitin-proteasome system to induce targeted protein degradation, have the potential to advance the field of personalized medicine for patients with lung cancer. Specifically, small molecule proteolysis targeting chimeras (PROTACs), consisting of two ligands connected by a linker that bind to a target protein and an E3 ubiquitin ligase, have been developed against many cancer targets, providing promising opportunities for advanced lung cancer. In this review, we focus on the rationale for PROTAC therapy as a new targeted therapy and the current status of PROTAC development in lung cancer.
Identifiants
pubmed: 36415148
pii: S1525-0016(22)00669-4
doi: 10.1016/j.ymthe.2022.11.011
pmc: PMC10014230
pii:
doi:
Substances chimiques
Proteasome Endopeptidase Complex
EC 3.4.25.1
Proteins
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
647-656Subventions
Organisme : NCI NIH HHS
ID : R01 CA234351
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE023641
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests G.Z. is co-founder of and has equity in Dialectic Therapeutics, which develops BCL-XL/2 PROTACs as cancer therapeutics.
Références
Angew Chem Int Ed Engl. 2020 Aug 17;59(34):14481-14489
pubmed: 32510788
Nat Rev Drug Discov. 2022 Mar;21(3):181-200
pubmed: 35042991
ACS Cent Sci. 2020 Aug 26;6(8):1367-1375
pubmed: 32875077
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
J Med Chem. 2022 Mar 10;65(5):3923-3942
pubmed: 35230841
J Med Chem. 2021 Jul 8;64(13):9152-9165
pubmed: 34138566
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Cancers (Basel). 2014 Mar 26;6(2):708-22
pubmed: 24675568
Eur J Med Chem. 2022 Jul 5;237:114373
pubmed: 35486993
Mol Cancer Ther. 2021 Aug;20(8):1367-1377
pubmed: 34045230
J Med Chem. 2018 Jan 25;61(2):462-481
pubmed: 28339196
Eur J Med Chem. 2021 Feb 15;212:113150
pubmed: 33453602
J Med Chem. 2020 Feb 13;63(3):1216-1232
pubmed: 31895569
Eur J Med Chem. 2022 Aug 5;238:114455
pubmed: 35594654
Nat Commun. 2021 Feb 10;12(1):920
pubmed: 33568647
Nat Rev Drug Discov. 2021 Oct;20(10):789-797
pubmed: 34285415
Science. 2017 Mar 17;355(6330):1158-1163
pubmed: 28302824
Sci Adv. 2020 Feb 21;6(8):eaay5154
pubmed: 32128407
Lancet Oncol. 2017 Nov;18(11):1454-1466
pubmed: 28958502
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Mol Cancer Ther. 2022 Jul 5;21(7):1060-1066
pubmed: 35499406
Cancer Cell. 2019 Nov 11;36(5):498-511.e17
pubmed: 31715132
Cell Chem Biol. 2018 Jan 18;25(1):67-77.e3
pubmed: 29129716
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Chembiochem. 2022 Jan 19;23(2):e202100270
pubmed: 34494353
J Med Chem. 2020 Apr 23;63(8):4069-4080
pubmed: 32223235
Front Cell Dev Biol. 2022 Apr 25;10:872729
pubmed: 35547806
J Hematol Oncol. 2022 Mar 9;15(1):23
pubmed: 35260176
Cancers (Basel). 2021 Jun 01;13(11):
pubmed: 34206026
Nat Rev Drug Discov. 2021 Apr;20(4):247-250
pubmed: 33737725
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
N Engl J Med. 2022 Jul 14;387(2):120-131
pubmed: 35658005
Eur J Med Chem. 2020 Apr 15;192:112199
pubmed: 32171162
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
Nat Rev Drug Discov. 2019 Dec;18(12):949-963
pubmed: 31666732
Cancer Res. 2020 Jun 1;80(11):2380-2393
pubmed: 32156781
Drug Des Devel Ther. 2019 Sep 06;13:3187-3198
pubmed: 31564835
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Cancer Gene Ther. 2022 Nov;29(11):1558-1569
pubmed: 35449204
Cell Chem Biol. 2020 Jan 16;27(1):19-31.e6
pubmed: 31883964
Am J Cancer Res. 2022 Feb 15;12(2):779-792
pubmed: 35261801
J Med Chem. 2018 Aug 09;61(15):6685-6704
pubmed: 30019901
Eur J Med Chem. 2021 Jun 5;218:113328
pubmed: 33773286
Nat Chem Biol. 2020 Nov;16(11):1170-1178
pubmed: 32778845
J Med Chem. 2021 Jul 8;64(13):9120-9140
pubmed: 34176264
J Med Chem. 2018 May 10;61(9):4249-4255
pubmed: 29660984
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
J Med Chem. 2022 Mar 24;65(6):4709-4726
pubmed: 35254067
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2773-8
pubmed: 18287036
Oncogene. 2020 Jun;39(26):4909-4924
pubmed: 32475992
Nat Commun. 2021 Nov 25;12(1):6896
pubmed: 34824248
Eur J Med Chem. 2018 May 10;151:304-314
pubmed: 29627725
J Am Chem Soc. 2018 Dec 12;140(49):17019-17026
pubmed: 30444612
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Eur J Med Chem. 2020 May 1;193:112190
pubmed: 32179332
Eur J Med Chem. 2022 Feb 15;230:114088
pubmed: 35007863
Pharm Res. 2022 Nov;39(11):2745-2759
pubmed: 35146591
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9
pubmed: 11438690
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514
pubmed: 35534623
Cell Rep. 2021 Feb 2;34(5):108707
pubmed: 33535033
ACS Med Chem Lett. 2022 Jan 14;13(2):278-283
pubmed: 35178183
Biochem Biophys Res Commun. 2018 Oct 28;505(2):542-547
pubmed: 30274779
Eur J Med Chem. 2021 May 5;217:113335
pubmed: 33751979
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
Eur J Med Chem. 2022 Aug 5;238:114509
pubmed: 35691176
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Chem Commun (Camb). 2021 Nov 30;57(95):12852-12855
pubmed: 34788776
Mol Cancer. 2022 Mar 7;21(1):67
pubmed: 35249548
N Engl J Med. 2021 Jun 24;384(25):2382-2393
pubmed: 34161704
J Med Chem. 2020 Jul 23;63(14):7510-7528
pubmed: 32437146
JCO Precis Oncol. 2021 Apr 22;5:
pubmed: 34250398
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Bioorg Chem. 2022 Mar;120:105605
pubmed: 35081479
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Chem Biol. 2015 Jun 18;22(6):755-63
pubmed: 26051217
Nat Med. 2019 Dec;25(12):1938-1947
pubmed: 31792461
Eur J Cancer. 2010 Jul;46(10):1773-80
pubmed: 20418096
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
Exp Cell Res. 2021 Nov 15;408(2):112868
pubmed: 34648846
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Eur J Med Chem. 2020 Dec 15;208:112781
pubmed: 32883633
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341